MORRISTOWN, N.J., June 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Columbia Laboratories, Inc. has filed with the ...
LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE ...
Columbia Labs’ Crinone is a vaginal progesterone gel which utilizes the company’s proprietary sustained-release bioadhesive technology. The product is currently approved in more than 60 countries. US ...
- Established, patient-preferred infertility treatment - - Expands Watson's Women's Health brand product portfolio - - Preterm birth clinical trials currently underway - - Company acquires 11.2 ...
Under the terms of the agreement, Watson paid Columbia an initial $47 million payment for exclusive progesterone gel product rights in the U.S. and received 11,200,000 million newly issued shares of ...
<0> Columbia Laboratories, Inc.Jonathan Lloyd Jones, 973-486-8818Vice President & CFOorThe Trout Group LLCSeth Lewis, 646-378-2952Senior Vice President </0> Columbia Laboratories, Inc. (NasdaqCM: CBRX ...
LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) has amended its license and supply agreement with Merck Serono, a division of Merck KGaA (XETRA: MRK.DE), Darmstadt, ...
* JUNIPER PHARMACEUTICALS INC - AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024 Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results